Patient recruitment has begun in a National Institutes of Health (NIH) trial of two digital therapeutics (DTx) for people with opioid use disorder (OUD), developed by Pear Therapeutics and
Artificial intelligence (AI) has the potential to improve the delivery of healthcare, but only if ethics and human rights are put at its heart of its design and use, according to the World
Former Cognoa executive Andy Molnar has been appointed chief executive of the Digital Therapeutics Alliance, a global trade association for companies developing evidence-based DTx products.
Novartis and Hewlett Packard Enterprise (HPE) have agreed to collaborate on the development of digital health technologies, starting with a project to develop a disease surveillance system
Digital health company Pear Therapeutics has foregone the traditional initial public offering (IPO) route to a stock exchange listing in favour of a merger with a "blank cheque" company.
Pharmaceutical sales and marketing operations have been forced to follow a steep learning curve as they adjust to operating within the rapidly evolving and hugely changed landscape caused b